Evidence map›Paper›PMID 32489416›Full record

ArticleJournal of the Intensive Care Society2020

Use of hemoadsorption in sepsis-associated ECMO-dependent severe ARDS: A case series.

Klaus Kogelmann, Morten Scheller, Matthias Drüner, Dominik Jarczak

Registry-linked trialOpen access · bronzeAbstract readCase Reports
In one paragraph

Article in Journal of the Intensive Care Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04742764 (Dosing of Extracorporeal Cytokine Removal In Septic Shock), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04742764 phase3suspendednot on this mapstarted 2024, after this paper: background citation

Dosing of Extracorporeal Cytokine Removal In Septic Shock (DECRISS): a Prospective, Randomized, Multicenter Clinical Trial

TypeinterventionalSponsorUniversity of PecsRan2024 to 2027Enrolled135ConditionsSeptic ShockArmsStandard medical therapy, Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 12 hours, Standard medical therapy plus cytokine removal treatment using Cytosorb, with the adsorber changed in every 24 hours
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Observational
  7. Review
  8. Review
  9. Article
  10. Therapeutic Modulation of the Host Defense by Hemoadsorption with CytoSorbInternational journal of molecular sciences · 2021
    Article
  11. Article
  12. Article
  13. Renal Replacement Techniques in Septic Shock.International journal of molecular sciences · 2021
    Review
  14. Article
  15. [Hemoadsorption for blood purification-incomparability of clinically available procedures].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2021
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Klaus KogelmannDepartment of Anesthesiology and Intensive Care Medicine, Klinikum Emden, Emden, Germany.
Morten SchellerDepartment of Anesthesiology and Intensive Care Medicine, Klinikum Emden, Emden, Germany.
Matthias DrünerDepartment of Anesthesiology and Intensive Care Medicine, Klinikum Emden, Emden, Germany.
Dominik JarczakDepartment of Intensive Care Medicine, University Hospital Hamburg, Hamburg, Germany.
Universität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcute respiratory distress syndrome in the context of severe sepsis and septic shock represents a serious clinical disorder. A recent case series in patients with septic shock and renal failure receiving hemoadsorption treatment showed rapid hemodynamic stabilization and increased survival, particularly in pneumonia patients and in those where therapy was started early. We hypothesized that patients suffering from pneumonia and refractory acute respiratory distress syndrome to the extent that they required extracorporeal membrane oxygenation support could possibly demonstrate the most pronounced benefit from the treatment.

methodsWe assessed the association of hemoadsorption treatment with hemodynamics, ventilation, and outcome variables in a set of patients with septic shock, acute respiratory distress syndrome, need for veno-venous extracorporeal membrane oxygenation, and continuous renal replacement therapy.

resultsKey observations include a significant stabilization in hemodynamics as evidenced by a marked decrease in catecholamine need, which was paralleled by a clear reduction in hyperlactatemia. Respiratory variables improved significantly. In addition, severity of illness and overall organ dysfunction showed a considerable decrease during the course of treatment. Observed mortality was approximately half as predicted by APACHE II. Treatment with CytoSorb was safe and well tolerated with no device-related adverse events. DISCUSSION: This is the first case series reporting on outcome variables associated to CytoSorb therapy in critically ill patients with septic shock, acute respiratory distress syndrome, veno-venous extracorporeal membrane oxygenation, and continuous renal replacement therapy. Based on our observations in this small case series, CytoSorb might represent a potentially promising therapy option for patients with refractory extracorporeal membrane oxygenation-dependent acute respiratory distress syndrome in the context of septic shock.

Indexed as

Acute respiratory distress syndromecontinuous renal replacement therapyCytoSorbextracorporeal membrane oxygenationhemoadsorptionseptic shock

Identifiers

PMID32489416
PMCPMC7238480
OpenAlexW2910328046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.